BRPI0408655A - formulações compreendendo um agente ativo e cacau em pó e a sua utilização - Google Patents

formulações compreendendo um agente ativo e cacau em pó e a sua utilização

Info

Publication number
BRPI0408655A
BRPI0408655A BRPI0408655-4A BRPI0408655A BRPI0408655A BR PI0408655 A BRPI0408655 A BR PI0408655A BR PI0408655 A BRPI0408655 A BR PI0408655A BR PI0408655 A BRPI0408655 A BR PI0408655A
Authority
BR
Brazil
Prior art keywords
cocoa powder
active agent
formulations
formulation
active
Prior art date
Application number
BRPI0408655-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Nils-Olof Lindberg
Katarina Eva Anette Lindell
Alice C Martino
Fredrik Per Nicklasson
Kristina Maarit Thyresson
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of BRPI0408655A publication Critical patent/BRPI0408655A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
BRPI0408655-4A 2003-03-26 2004-03-16 formulações compreendendo um agente ativo e cacau em pó e a sua utilização BRPI0408655A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300831A SE0300831D0 (sv) 2003-03-26 2003-03-26 New formulations and use therof
PCT/IB2004/000860 WO2004084865A1 (en) 2003-03-26 2004-03-16 Formulations comprising an active ingredient and cocoa powder and use thereof

Publications (1)

Publication Number Publication Date
BRPI0408655A true BRPI0408655A (pt) 2006-03-28

Family

ID=20290786

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408655-4A BRPI0408655A (pt) 2003-03-26 2004-03-16 formulações compreendendo um agente ativo e cacau em pó e a sua utilização

Country Status (13)

Country Link
EP (1) EP1605921A1 (es)
JP (2) JP2006521348A (es)
CN (1) CN1764440A (es)
AR (1) AR043772A1 (es)
AU (1) AU2004224557B2 (es)
BR (1) BRPI0408655A (es)
CA (1) CA2519155A1 (es)
CL (1) CL2004000564A1 (es)
MX (1) MXPA05010196A (es)
SE (1) SE0300831D0 (es)
TW (1) TW200503782A (es)
WO (1) WO2004084865A1 (es)
ZA (1) ZA200507719B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
CN101237850A (zh) * 2005-08-02 2008-08-06 德罗萨帕尔姆股份公司 含有吲哚美辛和/或阿西美辛的药物组合物
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CN102919739B (zh) 2007-06-13 2014-07-02 大塚制药株式会社 含雌马酚的提取物、其制备方法、雌马酚的提取方法及含雌马酚的食品
CN101444273B (zh) * 2007-11-22 2013-04-24 何煜 一种保健品口腔速释制剂及其制造方法
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
BRPI1012170A2 (pt) * 2009-05-20 2016-03-29 Lingual Consegna Pty Ltd formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
WO2014135967A1 (en) 2013-03-06 2014-09-12 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
CN103583781B (zh) * 2013-11-01 2015-11-25 阳波 咖啡味甲硝唑口香糖
US20170112762A1 (en) * 2014-06-10 2017-04-27 Capsugel Belgium Nv Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
JP6334482B2 (ja) * 2015-08-28 2018-05-30 中野Ｂｃ株式会社 固形剤とその製造方法
CN108430233A (zh) * 2015-12-09 2018-08-21 波维瓦茶业有限责任公司 包含亲脂性活性剂的稳定的即饮型饮料组合物
CA3176596A1 (en) * 2015-12-09 2017-06-15 Poviva Corp. Methods for formulating orally ingestible compositions comprising lipophilic active agents
EP3541393A4 (en) 2016-11-18 2020-06-17 The University Of Western Australia TASTE MASKING PRODUCT
EP3758675A1 (de) * 2018-03-01 2021-01-06 LTS Lohmann Therapie-Systeme AG Orale darreichungsform mit theobrominfreiem kakao
CN109053718B (zh) * 2018-08-09 2022-06-03 天津理工大学 一种罗格列酮糖精盐及其制备方法
CN111729087A (zh) * 2020-07-24 2020-10-02 成都大学 一种选择性β2受体激动剂的脂质修饰物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785574A (en) * 1955-03-29 1957-10-30 Pfizer & Co C Pharmaceutical compositions containing tetracycline antibiotics
GB918955A (en) * 1960-05-19 1963-02-20 Thomae Gmbh Dr K Pharmaceutical laxative compositions comprising 4,4-dihydroxy-2-amino triphenylmethane
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
JP2001106641A (ja) * 1999-10-06 2001-04-17 Tendou Seiyaku Kk 口内薬
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
JP2006521348A (ja) 2006-09-21
ZA200507719B (en) 2007-09-26
SE0300831D0 (sv) 2003-03-26
WO2004084865A1 (en) 2004-10-07
AU2004224557A1 (en) 2004-10-07
CL2004000564A1 (es) 2005-02-04
EP1605921A1 (en) 2005-12-21
AR043772A1 (es) 2005-08-10
CN1764440A (zh) 2006-04-26
MXPA05010196A (es) 2005-11-08
AU2004224557B2 (en) 2009-06-18
TW200503782A (en) 2005-02-01
CA2519155A1 (en) 2004-10-07
JP2011079841A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
UY27186A1 (es) Formulación farmacéutica
BR9911071A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido
ES2109832T3 (es) Composicion dermatologica o farmaceutica, procedimiento de preparacion y utilizacion
SE9704186D0 (sv) New composition of matter
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
BR0313627A (pt) Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores
BRPI0313148B8 (pt) formulações sólidas matriciais de lamotrigina contendo revestimento externo e perfuração em tal revestimento
SE9700885D0 (sv) New pharmaceutical formulation
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
BR0207654A (pt) Composição que compreende um creme ou loção base
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ATE353231T1 (de) Pharmazeutische zusammensetzungen
WO1999050239A3 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
ATE215367T1 (de) Nimesulid enthaltende pharmazeutische zubereitung zur topischen anwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 13A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)